Cars biontech share in red: production of omikron-adapted vaccine - biontech expects 2022 up to 17 billion euros vaccine sales
BionTech earns significantly more - BionTech share in Green
The Biotechnology Group BionTech has opened his books. © Provided by Finanzen.net Kazuhiro NOGI / AFP / GettyImages BionTech has recorded a winning jump in the third quarter of 2021. The earnings per share amounted to 12.35 euros after -0.880 euros before the year. The analyst estimates had in advance to € 10.54 per share certificate. Thus, Biontech scored a net profit of 3.2 billion euros. also revealed the proceeds and climbed to 6.1 billion euros.
the mainzer pharmaceutical company biontech and its US partner Pfizer have with the production of a corona-adapted to the omikron variant. Vaccine for later commercial use began. D
This shared-Kef Uugur Sahin on Tuesday on a Health Conference of US Bank J.P. Morgan with. At the end of January, a clinical trial to the vaccine will begin. "We assume that by March, we will be prepared for a delivery of the market if the regulatory approvals are available." The European Drug Authority (EMA) has not yet declared whether it considers that a vaccine adapted to omikron with a different composition as necessary for the currently used vaccine.
omikron variant: BIONTECH would have an updated version of his corona vaccine "in 100 days" finished
of the vaccine manufacturer Pfizer / Biontech explained that he produces an updated version of his Corona vaccine within a hundred days and bring to the market if the new omikron variant would be resistant to the current vaccine. Scientists from South Africa discovered the new variant first and informed the world public. Meanwhile, Omikron was proven in several other countries, including Israel, Great Britain and Belgium.
For the year 2022, BIONTECH andBionTech expects 2022 to 17 billion euros in vaccine sales go from a production capacity of up to four billion vaccine doses worldwide. "We expect that even in 2022 a strong demand for our vaccine exists," said Sahin in his online appearance.
Biontech expects this year to revenue up to 17 billion euros with its Covid 19 vaccine. Last year, sales as previously predicted at 16 to 17 billion euros. In 2022, Board of Directors Ugur Sahin is from a range of 13 to 17 billion, as evidenced by an investor presentation published on Tuesday.reaffirmed that a vaccine adapted to the omikron variant of the Coronavirus Coronavirus could already be available in the
March. Overall, the company continues to strive for a production capacity of up to four billion in vaccases this year.
The BionTech share temporarily recorded 4.41 percent in NASDAQ trading in minus $ 219.86. The Pfizer share at the NYSE temporarily returns by 0.41 percent to $ 56.01 to.Frankfurt (Reuters) / Mainz (DPA-AFX)
Biontech and Pfizer want to start testing for omikron vaccine before the end of January .
begin the vaccine manufacturer Pfizer and Biontech plan to test a vaccine adapted to the omikron variant before the end of January against the Corona virus to people. This explained by the scientific director of Pfizer to Business Insider. "We will test this from the end of January when we start clinical trials in which we compare the Omikron vaccine with the current vaccine," Mikael Dolfen said in a video interview on Monday.